AAAAAA

   
Results: 1-22 |
Results: 22
A RANDOMIZED, CONTROLLED, DOUBLE-BLIND-STUDY COMPARING THE SURVIVAL BENEFIT OF 4 DIFFERENT REVERSE-TRANSCRIPTASE INHIBITOR THERAPIES (3-DRUG, 2-DRUG, AND ALTERNATING DRUG) FOR THE TREATMENT OF ADVANCED AIDS
Authors: HENRY K ERICE A TIERNEY C BALFOUR HH FISCHL MA KMACK A LIOU SH KENTON A HIRSCH MS PHAIR J MARTINEZ A KAHN JO
Citation: K. Henry et al., A RANDOMIZED, CONTROLLED, DOUBLE-BLIND-STUDY COMPARING THE SURVIVAL BENEFIT OF 4 DIFFERENT REVERSE-TRANSCRIPTASE INHIBITOR THERAPIES (3-DRUG, 2-DRUG, AND ALTERNATING DRUG) FOR THE TREATMENT OF ADVANCED AIDS, Journal of acquired immune deficiency syndromes and human retrovirology, 19(4), 1998, pp. 339-349
NEW TESTING STRATEGY TO DETECT EARLY HIV-1 INFECTION FOR USE IN INCIDENCE ESTIMATES AND FOR CLINICAL AND PREVENTION PURPOSES
Authors: JANSSEN RS SATTEN GA STRAMER SL RAWAL BD OBRIEN TR WEIBLEN BJ HECHT FM JACK N CLEGHORN FR KAHN JO CHESNEY MA BUSCH MP
Citation: Rs. Janssen et al., NEW TESTING STRATEGY TO DETECT EARLY HIV-1 INFECTION FOR USE IN INCIDENCE ESTIMATES AND FOR CLINICAL AND PREVENTION PURPOSES, JAMA, the journal of the American Medical Association, 280(1), 1998, pp. 42-48
SAFETY, PHARMACOKINETICS, AND ANTIRETROVIRAL ACTIVITY OF INTRAVENOUS 9-[2-(R)-(PHOSPHONOMETHOXY)PROPYL]ADENINE A NOVEL ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) THERAPY, IN HIV-INFECTED ADULTS
Authors: DEEKS SG BARDITCHCROVO P LIETMAN PS HWANG F CUNDY KC ROONEY JF HELLMANN NS SAFRIN S KAHN JO
Citation: Sg. Deeks et al., SAFETY, PHARMACOKINETICS, AND ANTIRETROVIRAL ACTIVITY OF INTRAVENOUS 9-[2-(R)-(PHOSPHONOMETHOXY)PROPYL]ADENINE A NOVEL ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) THERAPY, IN HIV-INFECTED ADULTS, Antimicrobial agents and chemotherapy, 42(9), 1998, pp. 2380-2384
SEXUAL TRANSMISSION OF AN HIV-1 VARIANT RESISTANT TO MULTIPLE REVERSE-TRANSCRIPTASE AND PROTEASE INHIBITORS
Authors: HECHT FM GRANT RM PETROPOULOS CJ DILLON B CHESNEY MA TIAN H HELLMANN NS BANDRAPALLI NI DIGILIO L BRANSON B KAHN JO
Citation: Fm. Hecht et al., SEXUAL TRANSMISSION OF AN HIV-1 VARIANT RESISTANT TO MULTIPLE REVERSE-TRANSCRIPTASE AND PROTEASE INHIBITORS, The New England journal of medicine, 339(5), 1998, pp. 307-311
ACUTE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
Authors: KAHN JO WALKER BD
Citation: Jo. Kahn et Bd. Walker, ACUTE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION, The New England journal of medicine, 339(1), 1998, pp. 33-39
RISK BEHAVIOR FOR HIV-INFECTION IN PARTICIPANTS IN PREVENTIVE HIV VACCINE TRIALS - A CAUTIONARY NOTE
Authors: CHESNEY MA CHAMBERS DB KAHN JO
Citation: Ma. Chesney et al., RISK BEHAVIOR FOR HIV-INFECTION IN PARTICIPANTS IN PREVENTIVE HIV VACCINE TRIALS - A CAUTIONARY NOTE, Journal of acquired immune deficiency syndromes and human retrovirology, 16(4), 1997, pp. 266-271
PREDICTORS OF SURVIVAL IN HIV-INFECTED PERSONS WITH 50 OR FEWER CD4 CELLS MM(3)/
Authors: SPINO C KAHN JO DOLIN R PHAIR JP
Citation: C. Spino et al., PREDICTORS OF SURVIVAL IN HIV-INFECTED PERSONS WITH 50 OR FEWER CD4 CELLS MM(3)/, Journal of acquired immune deficiency syndromes and human retrovirology, 15(5), 1997, pp. 346-355
PHASE-1 TRIAL OF ANTI-CD22 RICIN-A-CHAIN IMMUNOTOXIN (IGG-RFB4-DGA) FOR TREATMENT OF AIDS-LYMPHOMA
Authors: KAPLAN LD ROBLES R KAHN JO SCHINDLER J GHETIE V VITETTA ES
Citation: Ld. Kaplan et al., PHASE-1 TRIAL OF ANTI-CD22 RICIN-A-CHAIN IMMUNOTOXIN (IGG-RFB4-DGA) FOR TREATMENT OF AIDS-LYMPHOMA, Journal of acquired immune deficiency syndromes and human retrovirology, 14(4), 1997, pp. 90-90
HIV-1 PROTEASE INHIBITORS - A REVIEW FOR CLINICIAN
Authors: DEEKS SG SMITH M HOLODNIY M KAHN JO
Citation: Sg. Deeks et al., HIV-1 PROTEASE INHIBITORS - A REVIEW FOR CLINICIAN, JAMA, the journal of the American Medical Association, 277(2), 1997, pp. 145-153
PROGNOSTIC VALUE OF PLASMA HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) RNA LEVELS IN PATIENTS WITH ADVANCED HIV-1 DISEASE AND WITH LITTLE OR NO PRIOR ZIDOVUDINE THERAPY
Authors: WELLES SL JACKSON JB YENLIEBERMAN B DEMETER L JAPOUR AJ SMEATON LM JOHNSON VA KURITZKES DR DAQUILA RT REICHELDERFER PA RICHMAN DD REICHMAN R FISCHL M DOLIN R COOMBS RW KAHN JO MCLAREN C TODD J KWOK S
Citation: Sl. Welles et al., PROGNOSTIC VALUE OF PLASMA HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) RNA LEVELS IN PATIENTS WITH ADVANCED HIV-1 DISEASE AND WITH LITTLE OR NO PRIOR ZIDOVUDINE THERAPY, The Journal of infectious diseases, 174(4), 1996, pp. 696-703
WEEKLY ORAL ETOPOSIDE IN PATIENTS WITH KAPOSIS-SARCOMA ASSOCIATED WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - A PHASE-I MULTICENTER TRIALOF THE AIDS CLINICAL-TRIALS GROUP
Authors: PAREDES J KAHN JO TONG WP FELDSTEIN ML LIN SL BENNETT JM METROKA CE RATNER L KROWN SE
Citation: J. Paredes et al., WEEKLY ORAL ETOPOSIDE IN PATIENTS WITH KAPOSIS-SARCOMA ASSOCIATED WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - A PHASE-I MULTICENTER TRIALOF THE AIDS CLINICAL-TRIALS GROUP, Journal of acquired immune deficiency syndromes and human retrovirology, 9(2), 1995, pp. 138-144
HIV CARE - A CHANGING HEALTH-CARE SYSTEM
Authors: KAHN JO SMITH MD
Citation: Jo. Kahn et Md. Smith, HIV CARE - A CHANGING HEALTH-CARE SYSTEM, Journal of acquired immune deficiency syndromes and human retrovirology, 8, 1995, pp. 1-3
HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 CANDIDATE VACCINE BREAKTHROUGH INFECTION - REPLY
Authors: KAHN JO
Citation: Jo. Kahn, HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 CANDIDATE VACCINE BREAKTHROUGH INFECTION - REPLY, The Journal of infectious diseases, 172(6), 1995, pp. 1637-1638
PREVALENCE AND CLINICAL-SIGNIFICANCE OF ZIDOVUDINE RESISTANCE MUTATIONS IN HUMAN-IMMUNODEFICIENCY-VIRUS ISOLATED FROM PATIENTS AFTER LONG-TERM ZIDOVUDINE TREATMENT
Authors: JAPOUR AJ WELLES S DAQUILA RT JOHNSON VA RICHMAN DD COOMBS RW REICHELDERFER PS KAHN JO CRUMPACKER CS KURITZKES DR
Citation: Aj. Japour et al., PREVALENCE AND CLINICAL-SIGNIFICANCE OF ZIDOVUDINE RESISTANCE MUTATIONS IN HUMAN-IMMUNODEFICIENCY-VIRUS ISOLATED FROM PATIENTS AFTER LONG-TERM ZIDOVUDINE TREATMENT, The Journal of infectious diseases, 171(5), 1995, pp. 1172-1179
CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OBSERVATIONS RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-I INFECTION IN A VOLUNTEER IN AN HIV-1 VACCINE CLINICAL-TRIAL
Authors: KAHN JO STEIMER KS BAENZIGER J DULIEGE AM FEINBERG M ELBEIK T CHESNEY M MURCAR N CHERNOFF D SINANGIL F
Citation: Jo. Kahn et al., CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL OBSERVATIONS RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE-I INFECTION IN A VOLUNTEER IN AN HIV-1 VACCINE CLINICAL-TRIAL, The Journal of infectious diseases, 171(5), 1995, pp. 1343-1347
ZIDOVUDINE COMPARED WITH DIDANOSINE IN PATIENTS WITH ADVANCED HIV TYPE-1 INFECTION AND LITTLE OR NO PREVIOUS EXPERIENCE WITH ZIDOVUDINE
Authors: DOLIN R AMATO DA FISCHL MA PETTINELLI C BELTANGADY M LIOU SH BROWN MJ CROSS AP HIRSCH MS HARDY WD MILDVAN D BLAIR DC POWDERLY WG PARA MF FIFE KH STEIGBIGEL RT SMALDONE L CRUMPACKER CS COOLEY T MITSUYASO RT JOHN R SANDERS C REITMAN D HEWITT R REICHMAN RC GELB LD MCGUIRE ML JONES M NEIDIG JL ZWICKL B HARTMAN PB ROARKE ME BURK RA FUHRER J SOMOGYI KA SEPKOWITZ K TELZAK EE MCAULIFFE VJ VALENTINE FT VASQUEZ M MERIGAN TC KATZENSTEIN D FESSELL J HAVLIR DV RICHMAN DD SPECTOR SA KAHN JO JOHNSON L COLEMAN R HO M MCMAHON D PAZIN G ANTONISKIS D MCNAMARA B DIAMOND D COLLIER AC PARADISE MA WALD A DEPAOLISJONES A HENRY K WASKIN HA HYSLOP NE MUSHATT DM ZACHARY JA SOEIRO R HARRIS C ZINGMAN B GIORDANO MF SLEDZ S MURRAY HW CAREY JT DAVIS TL BAGBY B KESSLER HA MURPHY RL HIRSCHTICK RE CHEESEMAN SH LAI KK FAIRCHILD PG EHMANN WC ZURLO JJ MILLARD R TROIANI L HEGGEN AA VANDERHORST CM MCKINLEY GF GRIECO MH KOLATCH BR GOLDSMITH JC GOMPERTS ED WOODS LM GRUE L MAYJO K BECKER RL JAYAWEERA DT ROLFE L COLE J JERMANO J
Citation: R. Dolin et al., ZIDOVUDINE COMPARED WITH DIDANOSINE IN PATIENTS WITH ADVANCED HIV TYPE-1 INFECTION AND LITTLE OR NO PREVIOUS EXPERIENCE WITH ZIDOVUDINE, Archives of internal medicine, 155(9), 1995, pp. 961-974
ZIDOVUDINE RESISTANCE AND HIV-1 DISEASE PROGRESSION DURING ANTIRETROVIRAL THERAPY
Authors: DAQUILA RT JOHNSON VA WELLES SL JAPOUR AJ KURITZKES DR DEGRUTTOLA V REICHELDERFER PS COOMBS RW CRUMPACKER CS KAHN JO RICHMAN DD
Citation: Rt. Daquila et al., ZIDOVUDINE RESISTANCE AND HIV-1 DISEASE PROGRESSION DURING ANTIRETROVIRAL THERAPY, Annals of internal medicine, 122(6), 1995, pp. 401-408
SAFETY AND IMMUNOGENICITY OF MN AND IIIB RGP120 HIV-1 VACCINES IN HIV-1-INFECTED SUBJECTS WITH CD4 COUNTS GREATER-THAN-500 CELLS/MM(3)/
Authors: ALLAN JD MITSUYASU R LAVELLE JP CONANT MA TWADDELL T KAHN JO
Citation: Jd. Allan et al., SAFETY AND IMMUNOGENICITY OF MN AND IIIB RGP120 HIV-1 VACCINES IN HIV-1-INFECTED SUBJECTS WITH CD4 COUNTS GREATER-THAN-500 CELLS/MM(3)/, AIDS research and human retroviruses, 10, 1994, pp. 190000157-190000157
SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GLQ223 IN PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX
Authors: KAHN JO GORELICK KJ GATTI G ARRI CJ LIFSON JD GAMBERTOGLIO JG BOSTROM A WILLIAMS R
Citation: Jo. Kahn et al., SAFETY, ACTIVITY, AND PHARMACOKINETICS OF GLQ223 IN PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX, Antimicrobial agents and chemotherapy, 38(2), 1994, pp. 260-267
CLINICAL AND IMMUNOLOGICAL RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE 1(SF2) GP120 SUBUNIT VACCINE COMBINED WITH MF59 ADJUVANT WITH OR WITHOUT MURAMYL TRIPEPTIDE DIPALMITOYL PHOSPHATIDYLETHANOLAMINE IN NON-HIV-INFECTED HUMAN VOLUNTEERS
Authors: KAHN JO SINANGIL F BAENZIGER J MURCAR N WYNNE D COLEMAN RL STEIMER KS DEKKER CL CHERNOFF D
Citation: Jo. Kahn et al., CLINICAL AND IMMUNOLOGICAL RESPONSES TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) TYPE 1(SF2) GP120 SUBUNIT VACCINE COMBINED WITH MF59 ADJUVANT WITH OR WITHOUT MURAMYL TRIPEPTIDE DIPALMITOYL PHOSPHATIDYLETHANOLAMINE IN NON-HIV-INFECTED HUMAN VOLUNTEERS, The Journal of infectious diseases, 170(5), 1994, pp. 1288-1291
URIC-ACID AND DIDANOSINE COMPLIANCE IN AIDS CLINICAL-TRIALS - AN ANALYSIS OF AIDS CLINICAL-TRIALS GROUP PROTOCOL-116A AND PROTOCOL-116B 117/
Authors: RICHARDSON D LIOU SH KAHN JO
Citation: D. Richardson et al., URIC-ACID AND DIDANOSINE COMPLIANCE IN AIDS CLINICAL-TRIALS - AN ANALYSIS OF AIDS CLINICAL-TRIALS GROUP PROTOCOL-116A AND PROTOCOL-116B 117/, Journal of acquired immune deficiency syndromes, 6(11), 1993, pp. 1212-1223
NEUROLOGICAL REACTIONS IN HIV-INFECTED PATIENTS TREATED WITH TRICHOSANTHIN
Authors: GARCIA PA BREDESEN DE VINTERS HV VONEINSIEDEL RG WILLIAMS RL KAHN JO BYERS VS LEVIN AS WAITES LA MESSING RO
Citation: Pa. Garcia et al., NEUROLOGICAL REACTIONS IN HIV-INFECTED PATIENTS TREATED WITH TRICHOSANTHIN, Neuropathology and applied neurobiology, 19(5), 1993, pp. 402-405
Risultati: 1-22 |